AMG 355
/ Amgen
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
March 18, 2026
Initial results of a phase 1 study of AMG 355, a novel anti-CCR8 antibody as a single agent and in combination with pembrolizumab in patients with solid tumors
(AACR 2026)
- "Abstract is embargoed at this time."
Clinical • Combination therapy • P1 data • Oncology • Solid Tumor • CCR8
February 23, 2026
20220028: Phase 1 First in Human Study to Explore AMG 355 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
(clinicaltrialsregister.eu)
- P1 | N=135 | Active, not recruiting | Sponsor: Amgen Inc. | Recruiting ➔ Active, not recruiting
Enrollment closed • First-in-human • Monotherapy • Colorectal Cancer • Gastric Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor
December 23, 2025
A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=77 | Active, not recruiting | Sponsor: Amgen | Trial completion date: Mar 2028 ➔ Aug 2026 | Trial primary completion date: Mar 2027 ➔ May 2026
First-in-human • Monotherapy • Trial completion date • Trial primary completion date • Colorectal Cancer • Gastric Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Solid Tumor
December 06, 2025
A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=77 | Active, not recruiting | Sponsor: Amgen | Recruiting ➔ Active, not recruiting | N=535 ➔ 77
Enrollment change • Enrollment closed • First-in-human • Monotherapy • Colorectal Cancer • Gastric Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Solid Tumor
October 17, 2025
A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=535 | Recruiting | Sponsor: Amgen | Trial completion date: Dec 2028 ➔ Mar 2028 | Trial primary completion date: Mar 2028 ➔ Mar 2027
First-in-human • Monotherapy • Trial completion date • Trial primary completion date • Colorectal Cancer • Gastric Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Solid Tumor
May 15, 2025
A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=535 | Recruiting | Sponsor: Amgen | Trial completion date: Feb 2028 ➔ Jan 2029 | Trial primary completion date: Feb 2027 ➔ Mar 2028
Monotherapy • Trial completion date • Trial primary completion date • Colorectal Cancer • Gastric Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Solid Tumor
March 12, 2024
A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=515 | Recruiting | Sponsor: Amgen | Not yet recruiting ➔ Recruiting
Combination therapy • Enrollment open • Metastases • Monotherapy • Colorectal Cancer • Lung Cancer • Oncology • Solid Tumor
1 to 7
Of
7
Go to page
1